Vor Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VOR Nasdaq 8731 https://www.vorbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vor Biopharma Inc

Vor Bio to Participate in the Goldman Sachs Healthcare Conference - Jun 5th, 2023 12:00 pm
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update - May 11th, 2023 8:05 pm
We Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth - Apr 19th, 2023 6:42 pm
Vor Bio to Participate in Upcoming Investor Conferences - Apr 18th, 2023 12:00 pm
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06% - Mar 28th, 2023 1:55 pm
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update - Mar 23rd, 2023 8:01 pm
Vor Biopharma Inc. (NASDAQ:VOR) Shares Could Be 43% Below Their Intrinsic Value Estimate - Mar 7th, 2023 10:52 am
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant - Feb 16th, 2023 7:04 pm
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level - Feb 16th, 2023 5:00 pm
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings - Jan 19th, 2023 1:00 pm
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference - Jan 12th, 2023 1:00 pm
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million - Dec 7th, 2022 12:45 pm
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™ - Dec 7th, 2022 12:30 pm
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $15 - Nov 30th, 2022 3:35 pm
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update - Nov 10th, 2022 9:15 pm
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely? - Oct 14th, 2022 2:26 pm
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer - Oct 12th, 2022 12:00 pm
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment - Oct 11th, 2022 12:00 pm
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters - Sep 28th, 2022 12:00 pm
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect? - Sep 1st, 2022 1:55 pm